BIO WITH BITE®

December 2018 • NASDAQ: MBIIInvestor Presentation

NASDAQ: MBIIBio With Bite®

Safe Harbor

2

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements,other than statements of historical facts, included in this press release regarding strategy, future operations and plans,including assumptions underlying such statements, are forward-looking statements, and should not be relied upon asrepresenting the Company’s views as of any subsequent date. Such forward-looking statements are based oninformation available to the Company as of the date of this presentation and involve a number of risks anduncertainties, some beyond the Company's control, that could cause actual results to differ materially from thoseanticipated by these forward-looking statements, including any difficulty in developing, manufacturing, marketing orselling the Company’s products, any failure to maintain and further establish relationships with distributors,competition in the market for pest management products, lack of understanding of bio-based pest managementproducts by customers and growers, adverse decisions by regulatory agencies, and the impact of negative publicity andperceptions around the company’s financial restatement. Additional information that could lead to material changes inthe Company’s performance is contained in its filings with the SEC. The Company is under no obligation to, and expresslydisclaims any responsibility to, update or alter forward-looking statements contained in this presentation, whether as aresult of new information, future events or otherwise.

This presentation references product shipments, a measure used by the Company that is not defined by, or presented inaccordance with, generally accepted accounting principles ("GAAP"), to evaluate various aspects of its business. Productshipments is a non-GAAP financial measure and should be considered in addition to, not as a substitute for, productrevenues reported in accordance with GAAP. Product shipments as used in this presentation is defined as productrevenues, plus related party product revenues, plus the incremental amount of deferred revenues accrued during theapplicable period from product shipments. This calculation specifically excludes changes in deferred revenue related tolicense revenues and customer deposits, and is intended to approximate the total value of products sold and undercontract for sale in a given period. Please refer to the Company’s filings with the SEC, including its earnings releases, fora reconciliation of product shipments to product shipments and further discussion of this metric.

© 2018 Marrone Bio Innovations, Inc.

NASDAQ: MBIIBio With Bite®

About Marrone Bio Innovations

3

▪ Only pure-play public biopesticide company in this disruptive, technology-driven market

▪ 7 existing commercial products with multibillion $ addressable global markets

▪ BIO is highest growth segment in $55 billion crop protection market

▪ In-house production capabilities & agreements with key distributors driving commercial margin & sales improvement

▪ Focused R&D supporting existing product improvements and pipeline of near-term products that meet unmet market needs

▪ Valuable patent and intellectual property portfolio

▪ Experienced management team with proven track record

NASDAQ: MBIIBio With Bite®

What Are Biologicals?

4

Biological Category

Biopesticides Biostimulants Biofertilizers

Use Crop Protection Crop Health Crop Nutrition

Regulatory EPA-Registered State Registered State Registered

New Entrants Few Many Many

MBI Products Yes (6 products) Yes (Haven®) No

NASDAQ: MBIIBio With Bite®

1) Marketsandmarketc.com 2016. Biopesticides Market by Type, Origin, Mode of Application, Formulation, & Crop Type - Global Forecast to 2022.2) Lux Research; 2015. An analysis of the biopesticide market now and where it is going.; Dunham Trimmer estimates. 3) Source: Blended numbers and CAGRs from BCC Research, marketsandmarkets, Agropages and Phillips McDougall4) Source: Agrow, Agrifutura and Phillips McDougall

▪ The current market opportunity for our 7 products exceeds $30B4

▪ The global biopesticides market is projected to reach $8.8B by 20221

▪ Biopesticides today are only 5% of the total crop protection market, representing significant room for growth2

▪ The biopesticide market is growing at a CAGR of ~17% vs. ~2.0% in the chemical pesticide market4

Rapidly Growing, Multi-Billion $ Market

5

$3.4B

$8.8B

Estimated Global Biopesticide Market1

NASDAQ: MBIIBio With Bite®

Why Are Growers Increasingly Adding Biologicals to Their Programs?

6

In both conventional & organic markets:

• Biologicals + Chemicals = better performance then either alone

• Improved yield and quality (better ROI)

• Sustainability goals = helps grower/food channel meet consumers’ demands

• Minimize risk of pest resistance

• Qualifies crops for higher value export markets = no residues

• Faster field re-entry = increases labor efficiency

• Low risk to pollinators, people and the environment = can help when chemicals are restricted or banned

NASDAQ: MBIIBio With Bite®

Our Biologicals Increase Growers’ ROIs

Organic

Biopesticide rotations and tank mixes

No Residues for Export

Early sprays & last spray before harvest

Conventional

In the tank with chemicals to enhance control, reduce resistance

1 2 3

• $1,400/Acre Increase

• >9X ROI

• 1,000 lb/Acre Increase(+12%)

• >4X ROI

• ~Seven bushel/Acre Increase

• >3X ROI

• 7,000-10,000 lb/Acre Increase

• Better Grade• >5X ROI

• +35% higher yield

• +$2,000/Acre• 20X ROI

7

Very High Conversion From “On-farm Demo” to Sale

• +17% higher yield

• 5-9X ROI

Grower ROI Drives Adoption (Examples)

NASDAQ: MBIIBio With Bite®

Strong Product PortfolioFinding Solutions for Pests, Diseases and Crop Stress

8

Product What is it? Category What Does it Do?

Knotweed extract

FungicidePlant health

• Controls plant diseases and improves plant health• Strong on powdery mildew

New strain of Bacillus bacteria

FungicidePlant health

• Controls plant diseases and improves plant health• Strong on downy mildews, white and gray molds

New species of bacteria

Insecticide• Stops feeding and reproduction of a broad range

of chewing and sucking insects, mites and flies

New species of bacteria

Insecticide• Stops development of a broad range of chewing

and sucking insects, mites and flies

New species of bacteria

Nematicide• Controls broad spectrum of root-feeding

nematodes to increase yields & quality

Coconut oil extract

Crop stress reduction

• Reduces sun & water stress, increasing yields & quality

New strain of bacteria

Molluscicide• Industry’s only biological solution for invasive

zebra & quagga mussels

NASDAQ: MBIIBio With Bite®

Biostimulant (yield and stress) State registrations only

Pipeline

9

Nematicide

Herbicide (burndown)MBI 011

MBI 303

EPA approved

NematicideMBI 302

Nematicide

MBI 005

EPA approved

See

king P

artne

rs

Herbicide (pre- and post emergence)

MBI 304

EPA approved (needs cost reduction)

EPA approved (needs mfg partner)

EPA approved

MBI 506-8

Ennoble™

EPA package largely developed

MBI 014

Nematicide

Herbicide (burndown)

EPA approved

Pip

elin

e

Herbicide EPA Submission in Progress

Nematicide

Nematicide EPA approved

Herbicide (pre- and post emergence) EPA approved (needs cost reduction)

EPA approved (needs mfg partner)

Biofumigant EPA approved

EPA package largely developed

Ne

ar T

erm

MBI’s current R&D is primarily focused on supporting existing commercial products; however, we have a very robust pipeline of products in queue

Nematicide

Pre-Development Development Regulatory Nat’l LaunchDiscovery

Strategic Collaborations

EPA approvedRegalia+Stargus

Regalia+Azoxy Biofungicide + Chemical Pre-mix EPA package in prep

Biofungicide Pre-mix EPA package in prep

NASDAQ: MBIIBio With Bite®

Marketing & Distribution Strategy

10

North America International

Regional & National Distributor/Retailer

In process with several local/regional companies for all world regionsDistributor/Retailer

MBI has a growing number of “on-farm” demos, to create grower pull-through demand, as well as educational seminars with distributors, which creates push-

through demand.

GrowerGrower

Regional & National Distributor/Retailer

Well established partnerships throughout the U.S.

NASDAQ: MBIIBio With Bite®

▪ Marrone Michigan Manufacturing (MMM) in Bangor, MI: purchased and retrofit for ~$15M with $10M USDA loan guarantee.

▪ Key benefits:

▪ Three 20,000L fermentation tanks; seed, formulation and mixing tanks, granulation, & centrifugation

▪ Rapidly scalable with demand. Future additions:

– Larger fermentation tanks

– Larger granulation capacity

– Add Venerate & Majestene capacity

▪ Current production: Regalia, Grandevo & Zequanox

Vertically Integrating Manufacturing

11

Controlled IP1

Flexible, Faster Scale-Up

Better Margins, Cost Controls & ROI3

2

NASDAQ: MBIIBio With Bite®

Our Competitive AdvantagesDeveloped & commercialized 7 New Active Ingredients in 11 years

12

In-house Discovery & In-licensed Technology

• Internally-discovered break-through products• Can rapidly develop others’ discoveries • Add our IP to in-licensed technology

Unique & Broad Screening Process

• We source, isolate and process our microbes differently• 18,000+ screened microorganisms; 350+ plant extracts• Tested against the broadest range of targets

Natural Product Chemistry Advantage

• Identify and patent natural compounds produced by our microbes

• Higher efficacy, broader spectrum and consistency• Understand mode of action; Stronger IP

Rapid Development &

Commercialization

• Targeted launch with key large growers• Highly bio-specialized R&D and commercial teams• Commercialized multiple products in record time

Formulation, Fermentation & Manufacturing

• Formulation and fermentation expertise = performance > chemicals

• Early elimination of strains that won’t scale • Process optimization capabilities can yield attractive

prices/margins

1

2

3

4

5

NASDAQ: MBIIBio With Bite®

Issued: 35 U.S. & 199 foreign patents; Pending: 31 U.S. & 146 foreign

Strong Patent Portfolio

13

• Novel strains and species • Pesticidal cDNA products• Specific uses for pest management

Microorganisms

• Individual compounds produced by the microorganism & their use for pest management

• Novel mixtures of compounds • Fermented and synthetic versions

NaturalProduct

Chemistry

• With other biological & chemical pesticidesMixtures

• Granules, liquids, powders, etc. of the microorganisms, plant extracts & their compoundsFormulations

• Addition of new uses such as seed & soil treatment & more pests

New Uses, New Pests

NASDAQ: MBIIBio With Bite®

MBI’s Unique & Agile Innovation Model

Biopesticide

3-5 Years & <$10 Million

Average Chemical Pesticide

~12 Years & $280 Million Development Time & CostDiscovery Launch

• Massive upfront capital

• Thousands of global field trials on many crops and pests

• Global launch with large marketing spend; Peak sales in 3 years

• Capital efficient but peak sales take longer

• EPA registration granted with small number of pests & crops on label

• Commercial development continues while selling

14

Discovery Launch

EPA submission of Version

1.0

V 1.0 Sales with early adopter

customers

V 2.0 developed

while waiting for

1.0 approval

V 2.0 placed with existing

and new customers

NASDAQ: MBIIBio With Bite®

Key Market Segments

15

0

100

200

300

400

500

600

700

US Row Crop Pesticide Market Size ($M)

Access via larger partners

Fruit, Vegetable, Nut & Vine –Primary MBI Focus with

Internal Resources

$2 BillionTAM

$1.5 BillionTAM

NASDAQ: MBIIBio With Bite®

Domestic Targets ($M)

Almonds$249

Tomatoes$172

Walnuts$39

Potatoes$136

Grapes$127

Oranges$113

Leafy$109

Apples$104

Cucurbits$80

Legume Veggies$37

Peaches$34

Cole Crops$33

Cherries$33

Plums$28

Onions$26

Cannabis$23

Market Attractiveness

Co

mp

etit

ive

Fit

Low High

High

Primary Focus Crops

Secondary Focus Crops

Key Focus Areas- Cannabis- Almonds- Grapes- Leafy Greens- Organic Crops- TerraConnect

o Seedo In-Furrowo Drip

16

In $M

NASDAQ: MBIIBio With Bite®

International Targets ($M)

Increasing Market Accessibility (Registration and Alignment)

Incr

ease

d M

arke

t A

ttra

ctiv

enes

s

Opportunistic Target Markets Current Strategic Target MarketSeeking Partners 17

$M

NASDAQ: MBIIBio With Bite®

Targeted Revenue Breakout – 2023

18

Seed Treatment11%

New Partnerships14%

International28%

Cannabis, Leafy Greens, Grapes,

Almonds33%

Potatoes, Oranges, Apples, Peaches, Plums, Cherries,

Tomatoes, Legume Veggies, Walnuts, Onions, Cucurbits,

Cole Crops14%

NASDAQ: MBIIBio With Bite®

$9

.1M

$9

.8M

$1

4.0

M

$1

8.2

M

FY14 FY15 FY16 FY17

Select Financials

19

(USD $ in Millions) TTM (9/30/18) TTM (9/30/17)

Revenue $18.8 $17.5

Net Income (Loss) ($19.9) ($31.4)

(USD $ in Millions) Sept 30, 2018 June 30, 2018

Cash & Cash Equivalents $20.5 $23.3

Debt1 $20.9 $21.8

Total Stockholder’s Equity $18.0 $22.0

• MBI has experienced above-industry average revenue growth, while keeping costs flat and increasing margins

1

February 2018: MBI closed comprehensive financing and debt restructuring transactions, by which the company received $27.3M in net proceeds and reduced outstanding debt by $45M

April 2018: MBI completed public offering, by which the company received $12.7M in net proceeds

1) Debt balance includes principal as well as interest deferred until 12/31/2022

NASDAQ: MBIIBio With Bite®

$9.1 $9.8

$14.0

$18.2

FY14 FY15 FY16 FY17

Annual GAAP Revenue ($M)CAGR = 19%

39%

45%

39%

41%

46%

48%47%

48.3%

Q416 Q117 Q217 Q317 Q417 Q118 Q218 Q318

$2

.7M

$3

.3M

$4

.2M

$4

.3M

$6

.5M

$5

.8M

$4

.2M

$5

.4M

Financial Performance Improving

20

Quarterly GAAP Revenue Operating Expenses Gross Margins

$7

.1M

$6

.6M

$7

.8M

$7

.6M $

7.9

M

$7

.2M

$8

.3M

$6

.8M

Percent Growth

-7% -3% -9% -19% Percent Growth

23% 4% -11% 29%

Achieved Record 48.3% Gross Margins in Q318

NASDAQ: MBIIBio With Bite®

Continuous Margin Enhancement

Greater Scale-50,000L @ Contractor

Achieved Yield Increases Potency Improvements

Same protection with less product

6X g/L 3X g/L 3X g/L

Overhead ↓Volume ↑Yields ↑

Additional yield increases in progress to reduce COGs

Strain Improvement Technologies

MBI-014

21

NASDAQ: MBIIBio With Bite®

▪ Only pure-play public biopesticide company in this disruptive, technology-driven market

▪ 7 existing commercial products with multibillion $ addressable global markets, above industry-average growth rates

▪ BIO is highest growth segment of ag inputs supported by favorable long-term trends

▪ In-house production capabilities & agreements with key distributors driving commercial margin & sales

▪ Focused R&D supporting existing products and pipeline of new, near-term products that meet unmet market needs

▪ Valuable patent and intellectual property portfolio

▪ Experienced management team with proven track record

Key Takeaways

22

1

NASDAQ: MBIIBio With Bite®

Contact Us

Company Contact:Pamela (Pam) MarroneFounder & CEOMain: 530-750-2800pmarrone@marronebio.comwww.marronebioinnovations.com

Investor Relations Contact:Greg FalesnikManaging Director – MZ North AmericaMain: 949-385-6449MBII@mzgroup.uswww.mzgroup.us

23